Prevalence of damaging genetic variants in genes of lipid metabolism pathway in Kazakhstani atherosclerosis cohort
Main Article Content
Authors
Zhanel Mirmanova
Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan, 010000
Madina Zhalbinova
Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan, 010000
Ayaulym Chamoieva
Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan, 010000
Tomiris Shakhmarova
Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan, 010000
Nazerke Satvaldina
Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan, 010000
Saule Rakhimova
Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan, 010000
Ulykbek Kairov
Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan, 010000
Asset Daniyarov
Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan, 010000
Makhabbat Bekbossynova
Heart Center, University Medical Center, Nazarbayev University, Astana, Kazakhstan, 010000
Ainur Akilzhanova
Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan, 010000
Abstract
Background: Atherosclerosis is a leading factor in cardiovascular diseases, and polymorphisms in the LDLR, APOB, PCSK9, GCKR, LPL, and APOE genes play a key role in lipid metabolism disorders. The aim of the study was to study the prevalence of genetic variations associated with lipid metabolism and their relationship to the risk of atherosclerosis in the population of Kazakhstan.
Materials and methods: The purpose of the study conducted in Kazakhstan was to identify a genetic predisposition to hyperlipidemia and its relationship to the risk of cardiovascular diseases. The study included 402 patients (23-65 years old) with pre-existing CVD, divided by risk levels according to ESC/EAS (2019) recommendations: very high (n=192), high (n=136) and low (n=74). All participants underwent complete exome sequencing with analysis of the GCKR, SLC22A5, LPL, FLCN, LDLR, and APOE genes; the data were processed using ANNOVAR, VarScan, and InterVar, and the classification of variants was performed according to ACMG/AMP criteria.
Results: Analysis of lipid metabolism genes in Kazakhstani patients with atherosclerosis has shown that the number of pathogenic (P) and likely pathogenic (LP) variants increases with increasing risk. The low-risk group has P and LP in APOE and GCKR, the high-risk group has P variants in APOE and MYO15A and some LP in APOE, GCKR, SLC22A5, and the very high- risk group has P in APOE and MYO15A, as well as all other LP in GCKR, SLC22A5, LPL, FLCN, LDLR, APOE. The total number of variants with uncertain significance also increased: 278 in 120 genes in the low-risk group, 460 in 136 genes in the high-risk group, and 615 in 145 genes in the very high-risk group. The correlation between the increase in P/LP mutations in APOE, SLC22A5, LDLR, and LPL and the high-risk group confirms their contribution to predisposition and progression of atherosclerosis in the Kazakhstani population.
Conclusion: An analysis of a Kazakh cohort of patients with atherosclerosis revealed a correlation between the level of cardiovascular risk and the accumulation of P and LP variants in genes regulating lipid metabolism, in particular APOE, SLC22A5, LDLR and LPL. The increase in the number of such variants, as well as the high frequency of VUS, emphasize the genetic determinacy of hyperlipidemia and the progression of atherosclerosis. The results of the study substantiate the need to integrate genetic screening into the risk stratification system and develop personalized strategies for the prevention of cardiovascular diseases in Kazakhstan.
Acknowledgement: Supported by the Committee of Science of the Ministry of Science and Higher Education of Republic of Kazakhstan (AP23490249), (AR19677442), (BR24993023), (BR24992841), (BR21881970) and Nazarbayev University CRP (211123CRP1608).
Key words: atherosclerosis, APOE, cardiovascular diseases, GCKR, hyperlipidemia